241 related articles for article (PubMed ID: 36051096)
1. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression.
Park S; Shin K; Kim IH; Hong T; Kim Y; Suh J; Lee M
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629433
[TBL] [Abstract][Full Text] [Related]
3. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
4. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
5. Characterization of zolbetuximab in pancreatic cancer models.
Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
[TBL] [Abstract][Full Text] [Related]
6. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Kayikcioglu E; Yüceer RO
Medicine (Baltimore); 2023 Feb; 102(6):e32882. PubMed ID: 36820561
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
8. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
9. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Wöll S; Schlitter AM; Dhaene K; Roller M; Esposito I; Sahin U; Türeci Ö
Int J Cancer; 2014 Feb; 134(3):731-9. PubMed ID: 23900716
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
11. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
12. Claudin-18 is an early-stage marker of pancreatic carcinogenesis.
Tanaka M; Shibahara J; Fukushima N; Shinozaki A; Umeda M; Ishikawa S; Kokudo N; Fukayama M
J Histochem Cytochem; 2011 Oct; 59(10):942-52. PubMed ID: 21832145
[TBL] [Abstract][Full Text] [Related]
13. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
14. AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.
Zou W; Yang Z; Li D; Liu Z; Zou Q; Yuan Y
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):40-47. PubMed ID: 30531392
[TBL] [Abstract][Full Text] [Related]
15. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
17. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
18. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
19. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
20. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
